Houston Methodist Hospital

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

Retrieved on: 
Tuesday, March 19, 2024
Retina, University of Nevada, Reno, Houston Methodist Hospital, Webcast, Associate, ASX, KOL, University, Doctor of Philosophy, MBA, University of Illinois Urbana-Champaign, Shore, AMD, FACS, Medicine, Pharmaceutical industry

Additionally, Opthea will provide a strategic outlook.

Key Points: 
  • Additionally, Opthea will provide a strategic outlook.
  • A live question and answer session will follow the formal presentations.
  • To register for this live webcast, click here .
  • A replay of the webcast will be made available on the Company’s website.

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Research, Pharmacology, LD, Survival, Serum, ALS, Science, PD, Houston Methodist Hospital, Patient, Regulatory affairs, Granulocyte-macrophage colony-stimulating factor, FD, GM-CSF, Nebraska Medicine, COYA, University, IPO, Senior, Society, IND, Commerce, Viral disease, Therapy, Frontotemporal dementia, FDA, FTD, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023.
  • COYA 302 is Coya’s combination of its proprietary LD IL-2 formulation with the immunomodulatory drug CTLA4-Ig.
  • “We believe that we have under-promised and over-delivered in executing on numerous deliverables in 2023 that have brought value to Coya,” commented Howard Berman, Ph.D., Chief Executive Officer of Coya.
  • Net loss was $8.0 million for the year ended December 31, 2023, compared to net loss of $12.2 million for the year ended December 31, 2022.

Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference

Retrieved on: 
Wednesday, March 6, 2024
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Central nervous system, Investigational New Drug, Houston Methodist Hospital, Chemokine, Frontotemporal dementia, Messenger, FDA, COYA, Conference, FTD, Therapy, Pathology, Patient, Poster, Role, IND, Pharmaceutical industry

The poster presentation was shared for the first time today at the AD/PD 2024 Conference in Lisbon, Portugal and can be found here .

Key Points: 
  • The poster presentation was shared for the first time today at the AD/PD 2024 Conference in Lisbon, Portugal and can be found here .
  • We intend to file an Investigational New Drug (IND) application with the FDA for COYA 302 in FTD later this year and initiate a Ph.
  • 2 trial in FTD patients shortly thereafter,” stated Fred Grossman, Chief Medical Officer at Coya Therapeutics.
  • In addition, several inflammation transcripts in monocyte genes known to be involved in neuroinflammatory signaling pathways were dysregulated in FTD, compared to controls.

Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”

Retrieved on: 
Wednesday, February 21, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, Coya, CD4, PD, Immune system, Houston Methodist Hospital, Frontotemporal dementia, Research, LD, Inflammation, Neuroinflammation, COYA, Animal, Letter, FTD, GM-CSF, Safety, University, Biomarker, Therapy, Patient, Survival, Oxidative stress, IND, Protein aggregation, Partnership, Pharmaceutical industry

Today, we announce that we are further expanding the pipeline for COYA 302, adding Alzheimer’s disease (AD) to its growing list of indications expected to be validated in the clinic.

Key Points: 
  • Today, we announce that we are further expanding the pipeline for COYA 302, adding Alzheimer’s disease (AD) to its growing list of indications expected to be validated in the clinic.
  • Beyond COYA 302, our therapeutic platform includes additional drug product combinations using COYA 301 (our proprietary LD IL-2) as their backbone.
  • 2 investigator-initiated trial with COYA 301 in AD that we expect will support the development of COYA 302 in that same indication.
  • I look forward to providing investors with additional periodic updates on our research, clinical, corporate, and commercial progress.

PHA's Weekend in Houston Spreads Pulmonary Hypertension Awareness April 6-7

Retrieved on: 
Thursday, February 22, 2024
Chest pain, Pulmonary hypertension, Master of Science, ATSF, Caregiver, Houston Methodist Hospital, Education, MD, Pulmonary Hypertension Association, Quality of life, Hospital, FCCP, Workshop, Empowerment, PHA, Fatigue, RSVP, Texas Children's Hospital, Patient, Survival, Disease, Diagnosis, Research, Pharmaceutical industry

WASHINGTON, Feb. 22, 2024 /PRNewswire-PRWeb/ -- The Pulmonary Hypertension Association visits Houston this spring for a weekend of pulmonary hypertension education, support and empowerment. The Houston weekend features two key events: The PHA Connects: PH Community Workshop on Saturday, April 6, and the 2024 Houston O2breathe Walk on Sunday, April 7.

Key Points: 
  • The Pulmonary Hypertension Association will be in Houston, April 6-7, hosting a weekend of events dedicated to raising pulmonary hypertension awareness and supporting the PH community in and around the Greater Houston area.
  • WASHINGTON, Feb. 22, 2024 /PRNewswire-PRWeb/ -- The Pulmonary Hypertension Association visits Houston this spring for a weekend of pulmonary hypertension education, support and empowerment.
  • The Houston weekend features two key events: The PHA Connects: PH Community Workshop on Saturday, April 6, and the 2024 Houston O2breathe Walk on Sunday, April 7.
  • The PHA Connects: PH Community Workshop will be on April 6, at the Westin Houston Medical Center.

2023 Urology Care Foundation Research Scholar Awardees Announced

Retrieved on: 
Tuesday, December 19, 2023
University, Vanderbilt University Medical Center, Cancer, Ageing, Urology, Pelvic pain, Houston Methodist Hospital, Spinal cord, The, EZH2, Randomized controlled trial, System, DNMT, Memorial, Weill Cornell Medicine, Children, Patient, American Urological Association, Hospital, FACS, Ureteroscopy, Research, Cornell University, AUA, Prostate cancer, Doctor of Philosophy, Macrophage, Funding of science, Children's Hospital of Philadelphia, Nursing

BALTIMORE, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) and the Urology Care Foundation, the official foundation of the AUA, are pleased to recognize 13 researchers as recipients of the 2023 Urology Care Foundation Research Scholar Awards.

Key Points: 
  • BALTIMORE, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) and the Urology Care Foundation, the official foundation of the AUA, are pleased to recognize 13 researchers as recipients of the 2023 Urology Care Foundation Research Scholar Awards.
  • Research Scholar Awards support future research leaders and ensure they receive the necessary training and guidance for a successful research career.
  • "The Urology Care Foundation is dedicated to improving urologic health worldwide by supporting research, providing patient education materials, and promoting humanitarian initiatives,” said Harris M Nagler, MD, FACS, Urology Care Foundation President.
  • “We are proud of our 2023 awardees and recognize the substantial impact their work will have on advancing the field of urology.”
    To learn more about the Urology Care Foundation Research Scholar Awards visit: https://www.auanet.org/research-and-data/research-awards/aua-funding/res...

Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Tuesday, November 14, 2023
JD, THR, Research, Safety, Chemistry, Acute leukemia, IND, PD, FXR, Clinical trial, SAD, Overweight, Fatty liver disease, Administration, Patient, DSM-IV codes, Tern, Week, Part, FDA, Obesity, Pharmacokinetics, BCR, Bangladesh Technical Education Board, Houston Methodist Hospital, Investigational New Drug, Non-alcoholic fatty liver disease, BCR-ABL, MD, CML, R, Research and development, NASH, DUET, Pharmaceutical industry, Medical imaging, Cryptocurrency

FOSTER CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today reported financial results for the quarter ended September 30, 2023 and provided corporate updates.

Key Points: 
  • Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2026.
  • Research and Development (R&D) Expenses: R&D expenses were $14.8 million for the quarter ended September 30, 2023, as compared with $12.2 million for the quarter ended September 30, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $18.4 million for the quarter ended September 30, 2023, as compared with $5.1 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $29.8 million for the quarter ended September 30, 2023, as compared with $16.8 million for the quarter ended September 30, 2022.

Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023
THR, Hepatology, Safety, Magnetic resonance imaging, Steatosis, AASLD, Liver, FXR, Clinical trial, Fatty liver disease, CT1, Patient, Week, Obesity, Houston Methodist Hospital, Non-alcoholic fatty liver disease, Bangladesh Technical Education Board, SHBG, MRI, Biomarker, NASH, DUET, Fibrosis, Pharmaceutical industry, Boston

FOSTER CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced the late-breaking oral presentation of top-line data from its Phase 2a DUET clinical trial of TERN-501, an investigational orally administered thyroid hormone receptor-β (THR-β) agonist for the treatment of NASH. TERN-501 was evaluated alone and in combination with the Company’s liver-distributed farnesoid X receptor (FXR) agonist TERN-101. These data will be presented at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), on Monday, November 13 at 2:00 p.m. ET in Boston, Massachusetts.

Key Points: 
  • TERN-501 was evaluated alone and in combination with the Company’s liver-distributed farnesoid X receptor (FXR) agonist TERN-101.
  • These data will be presented at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), on Monday, November 13 at 2:00 p.m.
  • “These top-line data of TERN-501 are encouraging, with significant reductions in key biomarkers including liver fat content, MRI-PDFF, and cT1, a marker of fibro-inflammation.
  • Terns will host an investor reception event during The Liver Meeting in Boston on Monday, November 13 at 4:00 p.m.

Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders

Retrieved on: 
Wednesday, December 13, 2023
Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Well, DRL, Research, Therapy, IND, Clinical trial, COYA, Commerce, Patient, Regulatory T cell, Oxidative stress, Neuroscience, Melinda French Gates, Houston Methodist Hospital, IPO, Drug discovery, Partnership, Coya, Drug, New business development, Letter, Inflammation, Pharmaceutical industry, Security (finance), ALS, Growth

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman.

Key Points: 
  • Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman.
  • Coya also successfully closed a private placement financing of $26.5 MM in gross proceeds, at a time when capital raising for biotech has been limited.
  • Because our C-suite team has “innovation DNA” ⏤ we think out of the box, we’re creative and we strive to execute rapidly.
  • We believe these data will provide important guidance for our development of COYA 301 (low dose IL-2) or COYA 302 in Alzheimer’s Disease.

Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Wednesday, December 6, 2023
Research, Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, NYSE, IND, Laboratory, COYA, Patient, Amyotrophy, Agreement, European, FDA, USD, BSE, Houston Methodist Hospital, Neurodegenerative disease, Partnership, NSE, RDY, Abatacept, Pharmaceutical industry, ALS, Coya

Reddy’s”), and Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya”), today announced that they have entered into a development and license agreement (the “Agreement”) for the development and commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Key Points: 
  • Reddy’s”), and Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya”), today announced that they have entered into a development and license agreement (the “Agreement”) for the development and commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS).
  • This Agreement is in addition to the in-licensing agreement with Dr. Reddy’s signed in early 20231.
  • Coya retains the right to commercialize COYA 302 for patients with amyotrophic lateral sclerosis (ALS) in Japan, Mexico, and each country in South America.
  • Coya will have responsibility for the clinical development of COYA 302 and for seeking regulatory approval for COYA 302 for patients with ALS in the United States.